Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Researchers at Stanford have developed genetically encoded STING agonists that enable controlled activation of the STING pathway from within engineered cells.
Researchers at Stanford have developed constitutively active, programmable synthetic cytokine receptors capable of polarizing human macrophages to a variety of user-defined cell states which may be useful for therapeutic applications.
Stanford researchers have developed a novel mutant IL-9 receptor (IL9R) that significantly enhances the in vivo engraftment, expansion, and anti-tumor activity of adoptively transferred T cells.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.
Stanford researchers have developed novel ENPP1 and ENPP3 inhibitors for cancer immunotherapy. ENPP1 inhibitors have previously been reported but ENPP3 is a newly discovered target.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.